title: Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
abstract: Chromosomal aberrations are important prognostic factors in multiple myeloma diagnosis. We evaluated the effect common high-risk chromosomal aberrations in a cohort of 102 patients with relapsed disease treated with bortezomib or thalidomide. Our results showed that patients treated with thalidomide with a gain(1)(q21) had inferior survival compared with the bortezomib group. Therefore, bortezomib-based regiments are more effective for patients with relapsed multiple myeloma with an incidence of gain in the gain(1)(q21).
  
  
  BACKGROUND
  Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described.
  
  
  METHODS
  We analyzed the prognostic value of an extended panel of chromosomal aberrations [del(13)(q14), del(17)(p13), t(4;14)(p16;q32), gain(1)(q21), and hyperdiploidy] by using the technique of interphase fluorescence in situ hybridization in a cohort of 102 patients with relapsed MM treated with thalidomide- or bortezomib-based protocols.
  
  
  RESULTS
  The gain(1)(q21) had a negative impact on overall survival for patients with MM treated with thalidomide (15.7 vs. 41.3 months; P = .004). Moreover, we confirmed the negative impact of the cumulative effect of 2 or more cytogenetic changes that occur simultaneously on the overall survival in the thalidomide group (20.3 months vs. not yet reached; P = .039). We did not find any significant impact of the aberrations studied on overall survival in the bortezomib cohort of patients.
  
  
  CONCLUSIONS
  We conclude that bortezomib-based protocols are able to partially overcome the negative prognostic impact of the tested chromosomal abnormalities in patients with relapsed MM.
authors.affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
authors.forename: Jan
authors.initials: J
authors.lastname: Smetana
authors.forename: Kristina
authors.initials: K
authors.lastname: Berankova
authors.forename: Romana
authors.initials: R
authors.lastname: Zaoralova
authors.forename: Pavel
authors.initials: P
authors.lastname: Nemec
authors.forename: Henrieta
authors.initials: H
authors.lastname: Greslikova
authors.forename: Renata
authors.initials: R
authors.lastname: Kupska
authors.forename: Aneta
authors.initials: A
authors.lastname: Mikulasova
authors.forename: Jan
authors.initials: J
authors.lastname: Frohlich
authors.forename: Sabina
authors.initials: S
authors.lastname: Sevcikova
authors.forename: Lucie
authors.initials: L
authors.lastname: Zahradova
authors.forename: Marta
authors.initials: M
authors.lastname: Krejci
authors.forename: Viera
authors.initials: V
authors.lastname: Sandecka
authors.forename: Martina
authors.initials: M
authors.lastname: Almasi
authors.forename: Petra
authors.initials: P
authors.lastname: Kaisarova
authors.forename: Hana
authors.initials: H
authors.lastname: Melicharova
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Adam
authors.forename: Miroslav
authors.initials: M
authors.lastname: Penka
authors.forename: Jiri
authors.initials: J
authors.lastname: Jarkovsky
authors.forename: Arthur
authors.initials: A
authors.lastname: Jurczyszyn
authors.forename: Roman
authors.initials: R
authors.lastname: Hajek
authors.forename: Petr
authors.initials: P
authors.lastname: Kuglik
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002869:Chromosome Aberrations; D002878:Chromosomes, Human, Pair 1; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D013792:Thalidomide / Q000627:therapeutic use*; D016896:Treatment Outcome; D014314:Trisomy
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib